JP2020523355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523355A5 JP2020523355A5 JP2019568646A JP2019568646A JP2020523355A5 JP 2020523355 A5 JP2020523355 A5 JP 2020523355A5 JP 2019568646 A JP2019568646 A JP 2019568646A JP 2019568646 A JP2019568646 A JP 2019568646A JP 2020523355 A5 JP2020523355 A5 JP 2020523355A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sarcoma
- patient
- liposarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010039491 Sarcoma Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 206010024627 Liposarcoma Diseases 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 4
- 206010073135 Dedifferentiated liposarcoma Diseases 0.000 claims 2
- 208000003991 Primitive Neuroectodermal Tumors Diseases 0.000 claims 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000006544 extraosseous Ewings sarcoma-primitive neuroepithelial tumor Diseases 0.000 claims 1
Claims (16)
- 軟部組織肉腫、または骨肉腫から選択されるその必要がある患者の肉腫の処置への使用のための、チノスタムスチンまたはその医薬的に許容される塩を含む医薬組成物。
- 肉腫がユーイングファミリーの腫瘍からである、請求項１に記載の医薬組成物。
- 肉腫が骨のユーイング腫瘍である、請求項２に記載の医薬組成物。
- 肉腫が骨外性ユーイング腫瘍である、請求項２に記載の医薬組成物。
- 肉腫が原始神経外胚葉腫瘍（ＰＮＥＴ）である、請求項２に記載の医薬組成物。
- 肉腫が脂肪肉腫である、請求項１に記載の医薬組成物。
- 脂肪肉腫が、高分化型脂肪肉腫、粘液型脂肪肉腫、多形型脂肪肉腫、または脱分化型脂肪肉腫である、請求項６に記載の医薬組成物。
- 脂肪肉腫が脱分化型脂肪肉腫である、請求項６に記載の医薬組成物。
- 肉腫が再燃性および／または不応性である、請求項１〜８のいずれか１項に記載の医薬組成物。
- チノスタムスチンまたはその医薬的に許容される塩が、０．３から３００ｍｇ／ｍ２患者体表面積、６０から１５０ｍｇ／ｍ２患者体表面積、または８０から１００ｍｇ／ｍ２患者体表面積の用量レベルで、その必要がある患者に静脈投与される、請求項１〜９のいずれか１項に記載の医薬組成物。
- チノスタムスチンまたはその医薬的に許容される塩が、２８日の処置サイクルの第１、８、および１５日にまたは２８日の処置サイクルの第１および１５日に、その必要がある患者に静脈投与される、請求項１〜１０のいずれか１項に記載の医薬組成物。
- チノスタムスチンまたはその医薬的に許容される塩が、６０分の輸液時間；または４５分の輸液時間；または３０分の輸液時間に渡って、その必要がある患者に静脈投与される、請求項１〜１１のいずれか１項に記載の医薬組成物。
- チノスタムスチンまたはその医薬的に許容される塩が、８０ｍｇ／ｍ２から１００ｍｇ／ｍ２患者体表面積の用量レベルで、２８日の処置サイクルの第１および１５日に、６０分の輸液時間に渡って、その必要がある患者に静脈投与される、請求項１〜１２のいずれか１項に記載の医薬組成物。
- 患者がチノスタムスチンまたはその医薬的に許容される塩および放射線療法によって処置される、請求項１〜１３のいずれか１項に記載の医薬組成物。
- 前記放射線療法処置が、連続５〜１０日間にわたって１から５Ｇｙ、好ましくは連続５〜１０日間にわたって２Ｇｙの線量で、その必要がある患者に与えられる、請求項１４に記載の医薬組成物。
- 軟部組織肉腫、または骨肉腫から選択される肉腫を処置するための説明書と一緒になったチノスタムスチンまたはその医薬的に許容される塩を含む、キット。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1709403.8 | 2017-06-13 | ||
| GBGB1709403.8A GB201709403D0 (en) | 2017-06-13 | 2017-06-13 | Compounds for treating sarcoma |
| PCT/EP2018/065668 WO2018229133A1 (en) | 2017-06-13 | 2018-06-13 | Tinostamustine for use in treating sarcoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020523355A JP2020523355A (ja) | 2020-08-06 |
| JP2020523355A5 true JP2020523355A5 (ja) | 2021-07-26 |
Family
ID=59358374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568646A Pending JP2020523355A (ja) | 2017-06-13 | 2018-06-13 | 肉腫を処置することへの使用のためのチノスタムスチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11576899B2 (ja) |
| EP (1) | EP3638232B1 (ja) |
| JP (1) | JP2020523355A (ja) |
| KR (1) | KR20200014791A (ja) |
| AR (1) | AR112144A1 (ja) |
| AU (1) | AU2018285822B2 (ja) |
| BR (1) | BR112019026463A2 (ja) |
| CA (1) | CA3067065A1 (ja) |
| ES (1) | ES2970224T3 (ja) |
| GB (1) | GB201709403D0 (ja) |
| IL (1) | IL271020A (ja) |
| MX (1) | MX2019015212A (ja) |
| TW (1) | TW201919618A (ja) |
| WO (1) | WO2018229133A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) * | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5882941A (en) | 1994-05-04 | 1999-03-16 | Massachusette Institute Of Technology | Programmable genotoxic agents and uses therefor |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| PT986403E (pt) | 1997-06-13 | 2004-04-30 | Cydex Inc | Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua |
| US6214852B1 (en) | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| AU2001273413A1 (en) | 2000-07-12 | 2002-01-21 | Immunex Corporation | Method for treating cancer using an interleukin- 4 antagonist |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| CN1764648A (zh) | 2003-01-13 | 2006-04-26 | 安斯泰来制药有限公司 | 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物 |
| US7652036B2 (en) | 2003-02-25 | 2010-01-26 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors |
| US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| CA2561617A1 (en) | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| UA99810C2 (ru) | 2005-05-13 | 2012-10-10 | Топотаргет Юк Лимитед | Фармацевтические составы, которые содержат ингибиторы деацетилазы гистонов |
| CN101528215B (zh) | 2006-10-20 | 2011-10-19 | 艾科斯有限公司 | Chk1抑制剂和环糊精的组合物 |
| GB0621160D0 (en) | 2006-10-24 | 2006-12-06 | Imp College Innovations Ltd | Compounds and uses thereof |
| DE602007009717D1 (de) | 2006-11-20 | 2010-11-18 | Cephalon Inc | Verfahren zur strahlensensibilisierung von tumoren mit einem strahlensensibilisierungsmittel |
| CN101084876A (zh) | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| US20090131367A1 (en) | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| WO2009100045A1 (en) | 2008-02-04 | 2009-08-13 | Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| EP2889029A1 (en) | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| MX2011003751A (es) | 2008-10-08 | 2011-04-27 | Cephalon Inc | Procesos para preparar bendamustina. |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| SI2389375T1 (sl) | 2009-01-23 | 2015-11-30 | Euro-Celtique S.A. | Derivati hidroksamske kisline |
| CN102421451B (zh) | 2009-02-25 | 2013-11-06 | 休普拉特克药品有限公司 | 苯达莫司汀环多糖组合物 |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| WO2011017448A1 (en) | 2009-08-05 | 2011-02-10 | The Trustees Of The University Of Pennsylvania | Use of histone deacetylase inhibitors for treatment of autoimmune diseases |
| CN101928234B (zh) | 2010-01-15 | 2012-12-12 | 北京欧凯纳斯科技有限公司 | 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法 |
| WO2011130689A1 (en) | 2010-04-15 | 2011-10-20 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| US9889147B2 (en) | 2010-04-16 | 2018-02-13 | Cellact Pharma Gmbh | Analogues of etoposide for the treatment of tumours |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| US8748470B2 (en) | 2011-03-17 | 2014-06-10 | The University Of Chicago | Methods for treating ovarian cancer by inhibiting fatty acid binding proteins |
| EP2755648B1 (en) * | 2011-09-13 | 2017-03-08 | Pharmacyclics LLC | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| CN102993102B (zh) | 2011-09-16 | 2016-08-24 | 杭州民生药业有限公司 | [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法 |
| AP3656A (en) * | 2011-09-18 | 2016-04-04 | Euro Celtique Sa | Pharmaceutical compositions |
| EP2760860B8 (en) | 2011-09-28 | 2017-03-08 | Euro-Celtique S.A. | Nitrogen mustard derivatives |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| WO2015085289A1 (en) | 2013-12-06 | 2015-06-11 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| NZ630314A (en) | 2014-02-18 | 2016-03-31 | Celgene Corp | Combination therapy for hematological malignancies |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| CN107438436A (zh) | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
| US20180311215A1 (en) | 2015-10-20 | 2018-11-01 | Hangzhou TINO Pharma Co., Ltd. | Pharmaceutical composition and preparation method therefor |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| US20180098969A1 (en) | 2016-10-11 | 2018-04-12 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| WO2020128913A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
-
2017
- 2017-06-13 GB GBGB1709403.8A patent/GB201709403D0/en not_active Ceased
-
2018
- 2018-06-13 EP EP18733530.2A patent/EP3638232B1/en active Active
- 2018-06-13 BR BR112019026463-9A patent/BR112019026463A2/pt not_active Application Discontinuation
- 2018-06-13 AR ARP180101623A patent/AR112144A1/es unknown
- 2018-06-13 MX MX2019015212A patent/MX2019015212A/es unknown
- 2018-06-13 ES ES18733530T patent/ES2970224T3/es active Active
- 2018-06-13 JP JP2019568646A patent/JP2020523355A/ja active Pending
- 2018-06-13 KR KR1020197037099A patent/KR20200014791A/ko not_active Application Discontinuation
- 2018-06-13 CA CA3067065A patent/CA3067065A1/en active Pending
- 2018-06-13 US US16/621,885 patent/US11576899B2/en active Active
- 2018-06-13 AU AU2018285822A patent/AU2018285822B2/en active Active
- 2018-06-13 TW TW107120396A patent/TW201919618A/zh unknown
- 2018-06-13 WO PCT/EP2018/065668 patent/WO2018229133A1/en active Application Filing
-
2019
- 2019-11-28 IL IL271020A patent/IL271020A/en unknown
-
2023
- 2023-02-13 US US18/108,736 patent/US20230277507A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523355A5 (ja) | ||
| JP2020523359A5 (ja) | ||
| JP2020523356A5 (ja) | ||
| JP2020523354A5 (ja) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| RU2020120593A (ru) | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом | |
| JP2008517991A5 (ja) | ||
| JP2012522837A5 (ja) | ||
| JP2019508476A5 (ja) | ||
| Shokri et al. | Osteoradionecrosis of the maxilla: conservative management and reconstructive considerations | |
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| Lee et al. | Eosinophilic granuloma in the anterior mandible mimicking radicular cyst | |
| Seok et al. | Proliferative periostitis of the mandibular ramus and condyle: a case report | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| Kim et al. | Managing intraoral lesions in oral cancer patients in a general dental practice: An overview | |
| Lee et al. | A needle penetrating the stomach cavity after acupuncture | |
| Rodda et al. | Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer | |
| Kassim et al. | Suppl 1: M2: Iatrogenic Damage to the Periodontium Caused by Radiation and Radiotherapy | |
| Delfino et al. | Combination treatment in CTCL: the current role of bexarotene | |
| Sultan | Mucormycosis (Black fungus): Newest threat post Covid-19 infection | |
| JP2018199726A5 (ja) | ||
| MX2021015467A (es) | Compuestos y metodos de uso. | |
| Youn et al. | Use of the pedicled buccal fat pad in the reconstruction of intraoral defects: a report of five cases | |
| Walia et al. | Osteoid osteoma of the mandible: a rare entity |